# The Effect of Rosuvastatin and Olmesartan on the Progression of Coronary Atherosclerotic Disease

Study · id `cardio:ct-nct02516826` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02516826](<https://clinicaltrials.gov/study/NCT02516826>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT02516826

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 504 participants.

## Technical summary

Registry record NCT02516826. Randomized; quadruple masking; primary purpose treatment. Start 2015-08 (registry gives no type); primary completion 2018-08 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 504 participants (planned count; ClinicalTrials.gov record NCT02516826, source copy `cardio:ctgov-nct02516826-2015-08-06`, retrieved 2026-10-31)
- Start date: 2015-08 (registry gives no type) (ClinicalTrials.gov record NCT02516826, source copy `cardio:ctgov-nct02516826-2015-08-06`, retrieved 2026-10-31)
- Primary completion: 2018-08 (anticipated) (ClinicalTrials.gov record NCT02516826, source copy `cardio:ctgov-nct02516826-2015-08-06`, retrieved 2026-10-31)
- Completion: 2018-08 (anticipated) (ClinicalTrials.gov record NCT02516826, source copy `cardio:ctgov-nct02516826-2015-08-06`, retrieved 2026-10-31)
- Countries: South Korea (ClinicalTrials.gov record NCT02516826, source copy `cardio:ctgov-nct02516826-2015-08-06`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02516826-2015-08-06`, retrieved 2026-10-31)

## The registry's words

- Brief title: The Effect of Rosuvastatin and Olmesartan on the Progression of Coronary Atherosclerotic Disease
- Condition: Coronary Syndrome
- Intervention (Drug): Rosuvastatin
- Intervention (Drug): Olmesartan
- Intervention (Drug): Combination
- Intervention (Drug): Placebo of Rosuvastatin
- Intervention (Drug): Placebo of Olmesartan
- Intervention (Drug): Placebo of Rosuvastatin/Olmesartan(Combination)
- Lead sponsor: Samsung Medical Center
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Unstable angina (`cardio:unstable-angina`)
- Registry intervention name matches this record: Rosuvastatin (`cardio:rosuvastatin`)
- Registry intervention name matches this record: Olmesartan (`cardio:olmesartan`)
- Registry lists this organization as the lead sponsor: Samsung Medical Center (`cardio:org-samsung-medical-center`)

## Provenance

Content hash: f2c5d4f463188cb773f9798ef2f3eaf8d824b6dba6d365bbf9575893dba49bc1
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
